Showing results (621-630 of 682) with videos related to

Sort By:
Pageof 69
British Journal of Haematology|January 13, 2011
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implicationsDouglas W McMillin, Jake Delmore, Joseph Negri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 1997
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donorsR J Soiffer, P Mauch, D Fairclough, et al.
Mayo Clinic Proceedings|July 13, 2004
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityPaul Richardson, Robert Schlossman, Sundar Jagannath, et al.
Blood|November 9, 2002
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.
American Journal of Hematology|June 2, 2011
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myelomaIrene M Ghobrial, Nikhil C Munshi, Brianna N Harris, et al.
Blood|April 9, 2004
The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistanceDharminder Chauhan, Guilan Li, Klaus Podar, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.
Blood|September 1, 2005
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaJohn G Gribben, David Zahrieh, Katherine Stephans, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Pageof 69